• david geldmacherThe Hugh Kaul Personalized Medicine Institute recently awarded two collaborative pilot implementation projects to advance precision medicine at UAB.

    David Geldmacher, M.D., professor in the Department of Neurology, will lead a project focused on using patient-specific genetic information to select medications to help attenuate behavioral and psychiatric symptoms in patients with dementia. Warner Huh, M.D., director of the Division of Gynecologic Oncology, and Rebecca Arend M.D., assistant professor in the Department of Obstetrics and Gynecology, will conduct molecular profiling on patients with recurrent ovarian cancer which may enable selection of more targeted treatment against the deadliest gynecologic cancer.
  • 150325115244 02 alzheimers woman exlarge 169There is no test doctors can use to conclusively determine whether someone will get Alzheimer's disease. "If you are in your 20s or 30s and want to know if you will get the disease, we don't have information to determine that now," said Heather Snyder, director of medical and scientific operations at the Alzheimer's Association.

    One thing everyone agrees on: There are a lot of unknowns when it comes to Alzheimer's disease. "We don't know the exact cause of Alzheimer's, we have hints and some pieces of information," Snyder said. One thing that is known, if you have a first-degree relative, such as a parent or sibling, with the disease, you are at an increased risk. "But that is by no means definitive that you will get the disease," she said. 

  • nathan schock centerThe University of Alabama at Birmingham has been named one of the country’s six Nathan Shock Centers of Excellence in the Basic Biology of Aging by the National Institutes of Health’s National Institute on Aging.

    The prestigious award, which amounts to more than $2.5 million over a five-year period, will support the establishment of UAB’s Nathan Shock Center.

  • Erik Roberson, M.D., Ph.D., associate professor in the Department of Neurology at the University of Alabama at Birmingham, is the winner of the 2015 Derek Denny-Brown Young Neurological Scholar Award from the American Neurological Association.

    The award, considered the ANA’s highest and most prestigious, recognizes early- to mid-career neurologists and neuroscientists who have made outstanding basic and clinical scientific advances toward the prevention, diagnosis, treatment and cure of neurological diseases.

  • Photo of Inga Kadish, Ph.D.Long-term administration of a drug that mimics the hunger-signaling hormone ghrelin protected Alzheimer’s disease-model mice from memory deterioration, despite a high-glycemic-index (GI) diet, according to research published in the journal Scientific Reports by University of Alabama at Birmingham investigator Inga Kadish, Ph.D., and colleagues.

  • graphic of a neuronResearchers at the University of Alabama at Birmingham and Southern Research are launching a new study to identify a novel therapy for treating Alzheimer’s disease. Funded by a grant of $250,000 from the BrightFocus Foundation, the new study grew from preliminary work funded by the Alabama Drug Discovery Alliance.

  • Photo of Robert Kessler, MDSeven weeks after weight-loss surgery, a group of women have seen significant changes in their body shapes and sizes. They’re each down 20 to 30 pounds, but that’s not the only change their bodies are going through.

    The women’s weight loss is caused by a change in appetite, which results from changes in brain function, explains UAB neuroradiologist Robert Kessler, M.D.